<DOC>
	<DOCNO>NCT02986100</DOCNO>
	<brief_summary>The purpose study characterize mass balance , absorption , metabolism , elimination pathway orally administer [ 14C ] rucaparib follow cycle cycle treatment rucaparib continue disease progression reason discontinuation</brief_summary>
	<brief_title>Absorption , Metabolism , Excretion Following Single Oral Dose 14C-Rucaparib</brief_title>
	<detailed_description>This Phase 1 , open-label , non-randomized , mass balance study patient histologically cytologically confirm advanced solid tumor . Approximately 6 patient enrol . The study consist 2 part : mass balance part ( Part I ) rucaparib treatment part ( Part II ) . Each patient receive single oral dose 600 mg [ 14C ] rucaparib ( approximately 140 ÂµCi ) fast state . Patients confine study site collection blood sample excreta maximum 13 day , Day -1 . The patient discharge sooner Day 13 , discharge criterion meet . If cumulative recovery radioactivity exceed 90 % administer dose radioactivity urine feces &lt; 1 % administer dose 24 hour period two consecutive day , determine quick count . In Part II , treatment rucaparib 28-day cycle continue progression disease , unacceptable toxicity , reason discontinuation .</detailed_description>
	<mesh_term>Rucaparib</mesh_term>
	<criteria>Histologically cytologically confirm advanced solid tumor Part II : Have know deleterious BRCA1/2 mutation ( germline somatic ) determine local central laboratory Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bone marrow , renal , liver function Prior treatment chemotherapy , radiation , antibody therapy immunotherapy , gene therapy , vaccine therapy , angiogenesis inhibitor within 14 day prior Day 1 Participation trial involve administration [ 14C ] label compound ( ) within last 6 month prior Day 1 Arterial venous thrombus ( include cerebrovascular accident ) , myocardial infarction , admission unstable angina , cardiac angioplasty , stenting within last 3 month prior Screening Preexisting duodenal stent , recent exist bowel obstruction , and/or gastrointestinal disorder defect would , opinion Investigator , interfere absorption rucaparib Untreated symptomatic central nervous system ( CNS ) metastases Evidence history bleed disorder Participation another investigational drug trial within 14 day prior Day 1 ( 5 time halflife drug , whichever long ) exposure three new investigational agent within 12 month prior Day 1 Acute illness ( eg , nausea , vomit , fever , diarrhea ) within 14 day prior Day 1 , unless mild severity approve Investigator Sponsor's/designated medical representative Active second malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>rucaparib</keyword>
	<keyword>CO-338</keyword>
	<keyword>Clovis</keyword>
	<keyword>Clovis Oncology</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>Absorption</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Excretion</keyword>
</DOC>